News & Updates

The phase 3 trial of the selective dopamine D1 receptor antagonist ecopipam has demonstrated maintenace of tic suppression for up to 24 weeks and reduction in the risk of relapse of 50 percent in children with Tourette syndrome.

Combination therapy with FOLFIRI-ramucirumab exhibits survival advantage similar to ramucirumab plus paclitaxel in patients with advanced upper gastrointestinal (UGI) cancers, reveals a study. However, FOLFIRI-ramucirumab is associated with a longer real-world time to treatment discontinuation (rwTTD).

Treatment with bempedoic acid helps lower low‐density lipoprotein cholesterol (LDL‐C) levels in Asian patients who have LDL-C elevations despite receiving lipid-lowering therapy, including statins, according to a study from Taiwan.

Children maintaining a sustained adherence rate of at least 85 percent to daily growth hormone therapy see a clinically meaningful improvement in growth over 2 years, as shown in a retrospective study.

Patients with HR+/HER2‒ breast cancer treated with immunotherapy show modest improvements in complete response rates, reports a study.

Intrathecal onasemnogene abeparvovec (OAV101 IT), a one-time gene transfer therapy, significantly improves motor function in treatment-naïve patients with spinal muscular atrophy (SMA), as shown by the period 1 results of the phase III STEER study.

Recent COVID-19 vaccination has been linked to a reduced risk of SARS-CoV-2 transmission in a prospective, case-ascertained household transmission study.